Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7092688

Augmentation malarplasty.

H G Brennan
View original source ↗Export metadata ↓

Abstract

The well-defined prominent high cheekbone is classically a sign of beauty in Western culture. Based on discussions with (1) representatives of Heyer-Schulte, Goleta, Calif, a leading manufacturer of malar implants regarding the demand for these implants, (2) other facial plastic surgeons, and (3) patients who are aware and request this procedure compared with other procedures in my practice, malar implants, available for the past few years, while effective, have not received universal acceptance and usage. The design limitations of the available implants and the bony resorption under the implant similar to what has been described in mentoplasty are discussed, as well as the long-term results using the standard implants, including photographic and radiographic findings. A modification in the shape of the malar implant and its advantages also will be discussed.

Explore related subjects

Bone ResorptionEstheticsFollow-Up StudiesHumansPostoperative ComplicationsProstheses and ImplantsRadiographySurgery, PlasticZygomaJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H G Brennan. 1982. Augmentation malarplasty.. https://doi.org/10.1001/archotol.1982.00790550045012

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Infantile hypophosphatasia: treatment options to control hypercalcemia, hypercalciuria, and chronic bone demineralization.

A 2-month-old child with infantile hypophosphatasia had hypercalcemia (3.49 mmol/L (14 mg/dl)), nephrocalcinosis, and diminished bone mineral content. Hypercalcemia was corrected with calcitonin. Hypercalciuria and bone demineralization abated with chlorothiazide. Hypercalcemia is hypothesized to be related to normal bone resorption in conjunction with impaired bone mineralization. Chlorothiazide may alleviate this impairment.

Bone Resorption↗
PubMed1997

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

Hypercalcaemia is an important cause of morbidity in malignant disease. We studied the efficacy and safety of intravenous ibandronate (a new, potent bisphosphonate) in a multicentre study of 147 patients with severe cancer-associated hypercalcaemia which had been resistant to treatment with rehydration alone. Of 131 randomized patients who were eligible for evaluation, 45 were allocated to receive 2 mg ibandronate, 44 patients to receive 4 mg and 42 patients to receive 6 mg. Serum calcium values fell progressively in each group from day 2, reaching a nadir at day 5, and in some patients normocalcaemia was maintained for up to 36 days after treatment. The 2-mg dose was significantly less effective than the 4-mg or 6-mg dose in correcting hypercalcaemia, as the number of patients who achieved serum calcium values below 2.7 mM after treatment was 50% in the 2-mg group compared with 75.6% in the 4-mg group and 77.4% in the 6-mg group (P < 0.05; 2 mg vs others). In a logistic regression analysis, three factors were found to predict response; ibandronate dose (higher doses were more effective), severity of presenting hypercalcaemia (severe hypercalcaemia was associated with less complete response) and tumour type (patients with breast carcinoma and haematological tumours responded better than those with other tumours). Ibandronate was generally well tolerated and no serious drug-related adverse events were observed. We conclude that ibandronate is a safe, well tolerated and effective treatment for cancer-associated hypercalcaemia, which should prove a useful addition to the current range of therapies available to treat this condition.

Bone Resorption↗
PubMed1997

Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.

Bisphosphonates are a new class of compounds with the ability to decrease bone resorption. Their mode of action appears to be complex, involving both a direct effect on the osteoclasts and an indirect one through osteoblasts. They are currently the drugs of choice in humans for Paget's disease and tumor bone disease, and are most useful in various types of osteoporosis. In view of their low toxicity, they are a most valuable addition to our therapeutic possibilities in the treatment of bone diseases.

Bone Resorption↗